Pablo G. Legorreta - May 8, 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
CEO, Chairman of the Board, Director
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta
Stock symbol
RPRX
Transactions as of
May 8, 2025
Transactions value $
$0
Form type
4
Date filed
5/9/2025, 05:18 PM
Previous filing
Feb 6, 2025
Next filing
May 14, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Legorreta Pablo G. CEO, Chairman of the Board, Director C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta 2025-05-09 0001507678

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Award $0 +288K +452% $0.00 352K May 8, 2025 Direct F1
holding RPRX Class A Ordinary Shares 460K May 8, 2025 By Legorreta Investments LLC
holding RPRX Class A Ordinary Shares 123K May 8, 2025 By IRRA
holding RPRX Class A Ordinary Shares 119K May 8, 2025 By SEP/IRA
holding RPRX Class A Ordinary Shares 1.04M May 8, 2025 By Legorreta Children 2002 Trust
holding RPRX Class A Ordinary Shares 902K May 8, 2025 By GST-Exempt Legorreta 2012 Family Trust
holding RPRX Class A Ordinary Shares 41.3K May 8, 2025 By GST-Exempt Legorreta 2020 Family Trust
holding RPRX Class A Ordinary Shares 6.93K May 8, 2025 By Spouse
holding RPRX Class A Ordinary Shares 292K May 8, 2025 By Tata MC 35 Ltd.
holding RPRX Class A Ordinary Shares 10K May 8, 2025 By Son
holding RPRX Class A Ordinary Shares 10K May 8, 2025 By Daughter
holding RPRX Class A Ordinary Shares 600K May 8, 2025 By Legorreta 2023 SR Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.